US Patent

US7326708 — Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor

Method of Use · Assigned to Merck and Co Inc · Expires 2026-04-11 · 0y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a dihydrogenphosphate salt of a dipeptidyl peptidase-IV inhibitor used for treating diabetes, obesity, and high blood pressure.

USPTO Abstract

The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1188 Zocor
U-1188 Zocor
U-1188 Zocor
U-1188 Zocor
U-1188 Zocor
U-1188 Zocor
U-802 sitagliptin-phosphate
U-802 sitagliptin-phosphate
U-2214 Steglatro
U-802 metformin-hydrochloride
U-1227 metformin-hydrochloride
U-1227 metformin-hydrochloride
U-802 sitagliptin-phosphate
U-1227 metformin-hydrochloride
U-802 metformin-hydrochloride
U-2214 Steglatro

Patent Metadata

Patent number
US7326708
Jurisdiction
US
Classification
Method of Use
Expires
2026-04-11
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.